COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease
R Fernandez-Ruiz, JL Paredes, TB Niewold - Translational Research, 2021 - Elsevier
As the world navigates the coronavirus disease 2019 (COVID-19) pandemic, there is a
growing need to assess its impact in patients with autoimmune rheumatic diseases, such as …
growing need to assess its impact in patients with autoimmune rheumatic diseases, such as …
Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review
M Taha, L Samavati - RMD open, 2021 - rmdopen.bmj.com
Background Many studies reported high prevalence of antiphospholipid antibodies (aPL) in
patients with COVID-19 raising questions about its true prevalence and its clinical impact on …
patients with COVID-19 raising questions about its true prevalence and its clinical impact on …
COVID‐19–related laboratory coagulation findings
KMJ Devreese - International journal of laboratory hematology, 2021 - Wiley Online Library
The alterations in the hemostatic balance in COVID‐19 patients are strongly disturbed and
contribute to a high prothrombotic status. The high rate of venous thromboembolism in …
contribute to a high prothrombotic status. The high rate of venous thromboembolism in …
COVID-19 and the antiphospholipid syndrome
Abstract Coronavirus disease 2019 (COVID-19) has resulted in a global pandemic. Most
COVID-19 patients are asymptomatic or have flu-like symptoms. However, around 15% of …
COVID-19 patients are asymptomatic or have flu-like symptoms. However, around 15% of …
COVID-19 and antiphospholipid antibodies
Antiphospholipid syndrome and the coagulopathy of COVID-19 share many
pathophysiologic features, including endotheliopathy, hypercoagulability, and activation of …
pathophysiologic features, including endotheliopathy, hypercoagulability, and activation of …
COVID-19 and antiphospholipid antibodies: time for a reality check?
Antiphospholipid antibodies (aPL) comprise a panel of autoantibodies that reflect a potential
prothrombotic risk in several autoimmune conditions, most notably antiphospholipid …
prothrombotic risk in several autoimmune conditions, most notably antiphospholipid …
Systematic review of antiphospholipid antibodies in COVID-19 patients: culprits or bystanders?
T Foret, V Dufrost, L Salomon Du Mont, P Costa… - Current Rheumatology …, 2021 - Springer
Purpose of Review COVID-19 patients have a procoagulant state with a high prevalence of
thrombotic events. The hypothesis of an involvement of antiphospholipid antibodies (aPL) …
thrombotic events. The hypothesis of an involvement of antiphospholipid antibodies (aPL) …
Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature
The term “lupus anticoagulant (LA)” identifies a form of antiphospholipid antibodies (aPLs)
causing prolongation of clotting tests in a phospholipid concentration-dependent manner …
causing prolongation of clotting tests in a phospholipid concentration-dependent manner …
Lupus anticoagulant single positivity during the acute phase of COVID‐19 is not associated with venous thromboembolism or In‐hospital mortality
N Gendron, MA Dragon‐Durey… - Arthritis & …, 2021 - Wiley Online Library
Objective The clinical relevance of antiphospholipid antibodies (aPLs) in COVID‐19 is
controversial. This study was undertaken to investigate the prevalence and prognostic value …
controversial. This study was undertaken to investigate the prevalence and prognostic value …
A novel multi-omics-based highly accurate prediction of symptoms, comorbid conditions, and possible long-term complications of COVID-19
Comprehensive clinical pictures, comorbid conditions, and long-term complications of
COVID-19 are still unknown. Recently, using a multi-omics-based strategy, we predicted …
COVID-19 are still unknown. Recently, using a multi-omics-based strategy, we predicted …